Neutrophil-Rich Infusion Site Reactions After Continuous Subcutaneous Application of Foslevodopa/Foscarbidopa

Mov Disord. 2025 Jan 11. doi: 10.1002/mds.30121. Online ahead of print.
No abstract available

Publication types

  • Letter